Kodiak Sciences (KOD) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Kodiak Sciences is set to announce its Q2 2025 earnings on August 13th, with analysts predicting an earnings per share of ($1.01).
• The company recently reported a Q1 loss of ($1.09) per share, missing estimates by ($0.20).
• Currently, 89.06% of Kodiak Sciences' shares are held by institutional investors, indicating strong interest from larger financial entities.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($1.01) per share for the quarter.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.20). On average, analysts expect Kodiak Sciences to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kodiak Sciences Stock Performance

Shares of NASDAQ KOD traded up $0.12 during mid-day trading on Wednesday, reaching $8.21. The company's stock had a trading volume of 482,041 shares, compared to its average volume of 658,986. The stock has a market capitalization of $433.16 million, a P/E ratio of -2.26 and a beta of 2.41. Kodiak Sciences has a 1-year low of $1.92 and a 1-year high of $11.60. The stock has a 50-day moving average of $4.78 and a two-hundred day moving average of $4.36.

Institutional Investors Weigh In On Kodiak Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in KOD. AQR Capital Management LLC purchased a new position in Kodiak Sciences during the first quarter worth about $188,000. Jane Street Group LLC raised its stake in shares of Kodiak Sciences by 441.3% in the 1st quarter. Jane Street Group LLC now owns 64,649 shares of the company's stock valued at $181,000 after acquiring an additional 52,705 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Kodiak Sciences in the 1st quarter worth approximately $94,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.